Table 2.
Resistome categories for carbapenem-resistant isolates in our prospective collection
| Resistance mechanism | # of CRE isolates | # of CSE isolates | % of total isolates in this category that are CRE | % of CRE isolates with this mechanism |
|---|---|---|---|---|
| i. Carbapenemases | 146 | 2 | 98.6% | 66.1% |
| AllblaKPC | 124 | 2 | 98.4% | 56.1% |
| blaKPC-3 | 60 | 1 | 98.4% | 27.1% |
| blaKPC-2 | 50 | 1 | 98.0% | 22.6% |
| blaKPC-4 | 11 | 0 | 100.0% | 5.0% |
| blaKPC(read based)a | 3 | 0 | 100.0% | 1.4% |
| AllblaNDM | 14 | 0 | 100.0% | 6.3% |
| blaNDM-1 | 11 | 0 | 100.0% | 5.0% |
| blaNDM-5 | 3 | 0 | 100.0% | 1.4% |
| AllblaSME | 6 | 0 | 100.0% | 2.7% |
| blaSME-1 | 3 | 0 | 100.0% | 1.4% |
| blaSME-2 | 3 | 0 | 100.0% | 1.4% |
| Other carbapenemases | 2 | 0 | 100.0% | 0.9% |
| blaIMP-84andblaKPC-4 | 1 | 0 | 100.0% | 0.5% |
| blaIMP-4 | 1 | 0 | 100.0% | 0.5% |
| ii. ESBL/AmpC + porin defect(s)b | 61 | 32 | 65.6% | 27.6% |
| Includes any ESBL | 46 | 11 | 80.7% | 20.8% |
| IncludesblaCTX-M-15 | 34 | 2 | 94.4% | 15.4% |
| IncludesblaSHV-12 | 11 | 5 | 68.8% | 5.0% |
| Includes other ESBLs | 13 | 5 | 72.2% | 5.9% |
| Includes any AmpC | 31 | 23 | 57.4% | 14.0% |
| IncludesblaEC | 19 | 8 | 70.4% | 8.6% |
| IncludesblaCMY-2 | 12 | 4 | 75.0% | 5.4% |
| Includes other AmpCs | 5 | 12 | 29.4% | 2.3% |
| iii. ESBL/AmpC without porin defect | 6 | 168 | 3.4% | 2.7% |
| iv. Porin defect(s) without ESBL/AmpC | 8 | 23 | 25.8% | 3.6% |
| Defect in both major porins | 5 | 5 | 50.0% | 2.3% |
| v. No known resistant determinants | 0 | 113 | 0.0% | 0.0% |